Recombinant Human Fas/CD95 Protein(HEK293) , His

DcR3, also known as TNFRSF6B, is a member of the tumor necrosis factor receptor (TNFR) superfamily, which plays a critical role in regulating immune responses. This decoy receptor can bind to various ligands, such as TRAIL (TNF-related apoptosis-inducing ligand), and prevent them from activating apoptosis in target cells. Its expression has been linked to various pathological conditions, including cancer, where it may contribute to tumor immune evasion by inhibiting apoptosis in tumor cells. The protein's ability to modulate apoptotic signaling pathways makes it a significant focus of research, particularly in understanding how tumors evade immune surveillance. Furthermore, DcR3 levels have been correlated with disease progression in several malignancies, suggesting its potential as a biomarker for cancer prognosis. The study of recombinant DcR3/TNFRSF6B proteins has garnered interest for their therapeutic implications, as modulating its interactions could enhance anti-tumor immunity or provide insights into cancer treatment strategies. By exploring the biochemical properties, signaling mechanisms, and the role of DcR3 in the immune microenvironment, researchers aim to develop novel therapeutic approaches that leverage its unique functions to combat cancer and other diseases linked to dysregulated apoptosis. Overall, the investigation of DcR3/TNFRSF6B not only enhances our understanding of immune regulation in health and disease but also opens avenues for new therapeutic interventions in oncology and beyond.